We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merrimack Pharmaceuticals Inc | NASDAQ:MACK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.07% | 14.74 | 14.74 | 14.75 | 14.76 | 14.72 | 14.72 | 25,997 | 16:54:56 |
CAMBRIDGE, Mass., Feb. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the formation of a new Scientific Advisory Board (SAB), comprised of world-renowned experts in precision oncology, including expertise in biomarker-defined cancers, bioengineering, drug discovery and clinical development. The SAB will work closely with Merrimack's senior management team to advance the company's robust pipeline of targeted cancer therapies.
"We are thrilled to have recruited such a distinguished group of experts to our scientific advisory board," said Richard Peters, M.D., Ph.D., President and CEO of Merrimack. "The SAB, and the strategic guidance they provide, will be an invaluable resource for Merrimack and we look forward to drawing on their expertise as we advance our novel precision therapeutics in biomarker-defined cancers."
The members of the Merrimack SAB are:
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of Merrimack's development programs, including four clinical studies and six candidates in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. For more information, please visit Merrimack's website at www.merrimack.com.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com
View original content:http://www.prnewswire.com/news-releases/merrimack-announces-formation-of-new-scientific-advisory-board-with-extensive-expertise-in-precision-oncology-300600820.html
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright 2018 PR Newswire
1 Year Merrimack Pharmaceuticals Chart |
1 Month Merrimack Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions